1-8 of 8
Richard Volckmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing

Apurva Gopisetty, Aniello Federico, Didier Surdez, Yasmine Iddir, Sakina Zaidi, Alexandra Saint-Charles, Joshua Waterfall, Elnaz Saberi-Ansari, Justyna Wierzbinska, Andreas Schlicker, Norman Mack, Benjamin Schwalm, Christopher Previti, Lena Weiser, Ivo Buchhalter, Anna-Lisa Böttcher, Martin Sill, Robert Autry, Frank Estermann, David Jones, Richard Volckmann, Danny Zwijnenburg, Angelika Eggert, Olaf Heidenreich, Fatima Iradier, Irmela Jeremias, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Petra Hamerlik, Maureen Hattersley, Olaf Witt, Louis Chesler, Alan Mackay, Johannes Gojo, Stefano Cairo, Julia Schueler, Johannes Schulte, Birgit Geoerger, Jan J. Molenaar, David J. Shields, Hubert N. Caron, Gilles Vassal, Louis F. Stancato, Stefan M. Pfister, Natalie Jaeger, Jan Koster, Marcel Kool, Gudrun Schleiermacher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 234.
https://doi.org/10.1158/1538-7445.AM2023-234
Published: 04 April 2023
View article titled, Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput <em>in vivo</em> testing
Journal Articles

Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

Aniello Federico, Apurva Gopisetty, Didier Surdez, Yasmine Iddir, Alexandra Saint-Charles, Justyna Wierzbinska, Andreas Schlicker, Richard Volckmann, Danny Zwijnenburg, Sara Colombetti, Olaf Heidenreich, Fatima Iradier, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Christina Guttke, Maureen M. Hattersley, Frédéric Colland, Ashley Strougo, María José Guillén, Louis Chesler, Chris Jones, Maria Eugénia Marques da Costa, Katia Scotlandi, Massimo Moro, Beat Schäfer, Marco Wachtel, Johannes Gojo, Walter Berger, Ángel Montero Carcaboso, Dennis Gürgen, Jens Hoffmann, Emilie Indersie, Stefano Cairo, Julia Schueler, Nicole Huebener, Johannes H. Schulte, Jan J. Molenaar, Birgit Geoerger, David J. Shields, Hubert N. Caron, Gilles Vassal, Lou F. Stancato, Lou F. Stancato, Stefan M. Pfister, Natalie Jäger, Jan Koster, Marcel Kool, Gudrun Schleiermacher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3571.
https://doi.org/10.1158/1538-7445.AM2023-3571
Published: 04 April 2023
View article titled, Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models
Journal Articles

Correction: Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors

Ellen M. Westerhout, Mohamed Hamdi, Peter Stroeken, Natalia E. Nowakowska, Arjan Lakeman, Jennemiek van Arkel, Nancy E. Hasselt, Boris Blejlevens, Nurdan Akogul, Franciska Haneveld, Alvin Chan, Peter van Sluis, Danny Zwijnenburg, Richard Volckmann, Carel JM van Noesel, Igor Adameyko, Tim van Gronigen, Jan Koster, Linda J. Valentijn, Johan van Nes, Rogier Versteeg
Journal: Cancer Research
Cancer Res (2022) 82 (14): 2657.
https://doi.org/10.1158/0008-5472.CAN-22-1915
Published: 18 July 2022
View article titled, Correction: Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors
Open the PDF for Correction: Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors in another window
Journal Articles

Abstract 2616: Stemness factors nanog and oct4 contribute to epithelial-to-mesenchymal transition and are predictive for outcome in esophageal adenocarcinoma

Amber Perenna van der Zalm, Mark P. Dings, Reimer Janssen, Peter Bailey, Jan Koster, Danny Zwijnenburg, Richard Volckmann, Cynthia Waasdorp, Jeroen Blokhuis, César Oyarce, Gerrit Hooijer, Sybren L. Meijer, Jan Paul Medema, Hanneke W. van Laarhoven, Maarten F. Bijlsma
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2616.
https://doi.org/10.1158/1538-7445.AM2022-2616
Published: 15 June 2022
View article titled, Abstract 2616: Stemness factors nanog and oct4 contribute to epithelial-to-mesenchymal transition and are predictive for outcome in esophageal adenocarcinoma
Journal Articles

Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors

Ellen M. Westerhout, Mohamed Hamdi, Peter Stroeken, Natalia E. Nowakowska, Arjan Lakeman, Jennemiek van Arkel, Nancy E. Hasselt, Boris Bleijlevens, Nurdan Akogul, Franciska Haneveld, Alvin Chan, Peter van Sluis, Danny Zwijnenburg, Richard Volckmann, Carel J.M. van Noesel, Igor Adameyko, Tim van Groningen, Jan Koster, Linda J. Valentijn, Johan van Nes, Rogier Versteeg
Journal: Cancer Research
Cancer Res (2022) 82 (3): 484–496.
https://doi.org/10.1158/0008-5472.CAN-21-1621
Published: 02 February 2022
View article titled, Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors
Open the PDF for Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract 2490: R2: Genomics analysis and visualization platform

Jan Koster, Richard Volckmann, Danny Zwijnenburg, Piet Molenaar, Rogier Versteeg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2490.
https://doi.org/10.1158/1538-7445.AM2019-2490
Published: 01 July 2019
View article titled, Abstract 2490: R2: Genomics analysis and visualization platform
Journal Articles

RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma

Thomas F. Eleveld, Linda Schild, Jan Koster, Danny A. Zwijnenburg, Lindy K. Alles, Marli E. Ebus, Richard Volckmann, Godelieve A. Tijtgat, Peter van Sluis, Rogier Versteeg, Jan J. Molenaar
Journal: Cancer Research
Cancer Res (2018) 78 (21): 6297–6307.
https://doi.org/10.1158/0008-5472.CAN-18-1045
Published: 01 November 2018
View article titled, RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma
Open the PDF for RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract #3208: Ornithine decarboxylase and antizyme 2 are prognostic markers for aggressive neuroblastoma independent of MYCN amplification status

Andre Bachmann, Jan Koster, David Albert, Dana-Lynn Koomoa, David Feith, Anthony Pegg, Richard Volckmann, Huib Caron, Rogier Versteeg, Dirk Geerts
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3208.
Published: 01 May 2009
View article titled, Abstract #3208: Ornithine decarboxylase and antizyme 2 are prognostic markers for aggressive neuroblastoma independent of <em>MYCN</em> amplification status